1-5 of 5
Liang Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax

Available to Purchase
Toshihisa Satta, Lin Li, Sri Lakshmi Chalasani, Xiaoyan Hu, Jewel Nkwocha, Kanika Sharma, Maciej Kmieciak, Mohamed Rahmani, Liang Zhou, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1332–1343.
https://doi.org/10.1158/1078-0432.CCR-22-2729
Published: 03 April 2023
View articletitled, Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
Open the PDF for Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax in another window
Includes: Supplementary data
Journal Articles

The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo

Available to Purchase
Yu Zhang, Liang Zhou, Dipankar Bandyopadhyay, Kanika Sharma, Alexander Joseph Allen, Maciej Kmieciak, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6195–6205.
https://doi.org/10.1158/1078-0432.CCR-18-3788
Published: 15 October 2019
View articletitled, The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo
Open the PDF for The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer

Available to Purchase
Abhilasha Nair, Steven J. Lemery, Jun Yang, Anshu Marathe, Liang Zhao, Hong Zhao, Xiaoping Jiang, Kun He, Gaetan Ladouceur, Amit K. Mitra, Liang Zhou, Emily Fox, Stephanie Aungst, Whitney Helms, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5205–5208.
https://doi.org/10.1158/1078-0432.CCR-15-1377
Published: 30 November 2015
View articletitled, FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer
Open the PDF for FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer in another window
Journal Articles

Abstract B15: Targeting SQSTM1/p62 induces cargo-loading failure and converts autophagy to apoptosis via NBK/Bik in human multiple myeloma cells.

Free
Yun Dai, Shuang Chen, Liang Zhou, Yu Zhang, Yun Leng, Xin-Yan Pei, Hui Lin, Richard Jones, Orlowski Robert, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): B15.
https://doi.org/10.1158/1557-3265.HEMMAL14-B15
Published: 19 August 2015
View articletitled, Abstract B15: Targeting SQSTM1/p62 induces cargo-loading failure and converts autophagy to apoptosis via NBK/Bik in human multiple myeloma cells.
Journal Articles

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial

Available to Purchase
Martha Donoghue, Steven J. Lemery, Weishi Yuan, Kun He, Rajeshwari Sridhara, Stacy Shord, Hong Zhao, Anshu Marathe, Lori Kotch, Josephine Jee, Ying Wang, Liang Zhou, William M. Adams, Vaishali Jarral, Anne Pilaro, Richard Lostritto, Joseph E. Gootenberg, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1496–1505.
https://doi.org/10.1158/1078-0432.CCR-11-2149
Published: 14 March 2012
View articletitled, Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial
Open the PDF for Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a “Physician's Choice” Control Arm in a Randomized Approval Trial in another window